Allelic heterogeneity in disease-causing genes presents a substantial challenge to the translation of genomic variation into clinical practice. Few of the almost 2,000 variants in the cystic fibrosis transmembrane conductance regulator gene CFTR have empirical evidence that they cause cystic fibrosis. To address this gap, we collected both genotype and phenotype data for 39,696 individuals with cystic fibrosis in registries and clinics in North America and Europe. In these individuals, 159 CFTR variants had an allele frequency of ≥0.01%. These variants were evaluated for both clinical severity and functional consequence, with 127 (80%) meeting both clinical and functional criteria consistent with disease. Assessment of disease penetrance in 2,188 fathers of individuals with cystic fibrosis enabled assignment of 12 of the remaining 32 variants as neutral, whereas the other 20 variants remained of indeterminate effect. This study illustrates that sourcing data directly from well-phenotyped subjects can address the gap in our ability to interpret clinically relevant genomic variation.
A r t i c l e s The usefulness of genetic testing for both mendelian and polygenic disorders is limited by the substantial number of DNA variants of uncertain significance [1] [2] [3] [4] . Next-generation sequencing in clinical laboratories will dramatically increase the number of variants of potential medical relevance 5 . Thus, an ever-widening gap is likely to occur between the ability to identify DNA variation and the ability to interpret its consequence 6 . One approach to address this gap is to aggregate variants identified by clinical and research laboratories into central repositories 7, 8 . Observation of the same variant in individuals with the same phenotype supports the notion that the variant may be deleterious. However, physicians request clinical testing for a number of reasons, including confirmation or exclusion of a specific diagnosis. Aggregation of variants from testing facilities without robust phenotype and functional annotation can diminish the potential clinical value of repositories 9, 10 .
A prime example of the challenge of allelic heterogeneity is the gene responsible for cystic fibrosis, the cystic fibrosis transmembrane conductance regulator gene CFTR (NM_000492.3). Almost 2,000 variants have been reported in the CFTR coding and flanking sequences, but the disease liability of only a few dozen variants has been ascertained 11 . Consequently, sequence analysis of the CFTR gene for diagnostic purposes frequently uncovers variants of uncertain significance. The clinical implications of incomplete annotation of CFTR sequence variation extend well beyond the ~70,000 individuals with cystic fibrosis worldwide, particularly because CFTR genetic testing is frequently part of newborn screening [12] [13] [14] [15] . Furthermore, populationbased screening for carriers of cystic fibrosis has become progressively more common, with an estimated 1.2 million individuals tested each year in the United States 16, 17 . In cases where one member of a couple is discovered to carry a known cystic fibrosis-causing variant, extensive CFTR analysis is often performed on the other member that identifies variants of uncertain significance 18 . Finally, the large number of non-experimentally verified disease-associated variants hampers understanding of how structural changes in the CFTR protein lead to dysfunction and result in the cystic fibrosis phenotype. The gap in understanding of disease-causing versus neutral alleles presents a major challenge in the genomic sequencing era.
Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene A central repository for CFTR variants termed the Cystic Fibrosis Mutation Database (CFMD; see URLs) began in 1990, shortly after the CFTR gene was identified. CFMD content was generated from discoveries in research laboratories, with additional contributions from genetic testing facilities. Although it provides an extensive collection of variation in CFTR, CFMD has little phenotypic annotation, and functional consequences of variation are primarily derived from predictions based on the nature of the nucleotide changes. Assessing the disease liability of CFTR variants with predictive algorithms has proven to be of limited usefulness 19, 20 . A key weakness in the development of more accurate algorithms is the paucity of variants with well-defined functional consequences 21 .
As the CFMD constituted an excellent existing repository of nucleotide variation in CFTR, we took a new approach to comprehensively address the phenotypic and functional implications of CFTR variants. Our Clinical and Functional TRanslation of CFTR (CFTR2) project assembled clinical data and accompanying CFTR variants from individuals with cystic fibrosis enrolled in national registries and large clinical centers from 24 countries. By focusing on variants present in individuals with a diagnosis of cystic fibrosis ascertained by expert clinicians, the project used a 'phenotype-driven' approach to data collection rather than the laboratory-based 'genotype-driven' approach. Second, microattribution recognition was used to identify the source and credit the contributors of the clinical and genetic data that constitute the CFTR2 database 22, 23 . To prioritize evaluation, the CFTR2 project started with the subset of CFTR variants exceeding an allele frequency of 0.01% in the collected individuals with cystic fibrosis. We used clinical features of subjects and functional assessment of each variant to define disease-causing variants. We evaluated variants not meeting clinical or functional thresholds for disease penetrance using a population-based approach. The phenotype-driven approach presented here could be used to inform the assignment of disease liability in a wide range of genetic disorders.
RESULTS

CFTR variants represent 96% of cystic fibrosis alleles
Data from the 39,696 individuals with cystic fibrosis in CFTR2 ( Fig. 1) were collected from national cystic fibrosis patient registries or cystic fibrosis specialty clinics ( Supplementary Table 1 ) and represent 57% of the estimated 70,000 individuals with cystic fibrosis 24 . Informed consent was obtained by the participating registry or clinic according to local requirements. The vast majority (95% of the 31,727 individuals with ancestry data) are listed as Caucasian. In these individuals, 1,044 distinct CFTR variants were seen. The most common variant, p.Phe508del, accounted for 70% of the identified alleles in these individuals. Twenty-two additional variants previously defined as cystic fibrosis causing and reported to occur at a frequency of 0.1% or higher in individuals with cystic fibrosis by the American College of Medical Genetics (ACMG) represented 17.5% of the alleles 11 . Another 136 variants occurred at a frequency exceeding 0.01% and were each reported on at least 9 alleles in the CFTR2 database ( Supplementary  Table 2 ). Together, these 159 variants accounted for 96.4% of the identified cystic fibrosis alleles in CFTR2. Our efforts focused on the evaluation of the disease liability of these 159 variants to maximize clinical sensitivity for cystic fibrosis genetic testing.
Phenotypic analysis
All individuals in the CFTR2 database were clinically diagnosed with cystic fibrosis; however, cystic fibrosis is a highly variable disorder 25 . To evaluate individuals across the spectrum of cystic fibrosis severity, we used sweat chloride concentration, a biochemical phenotype that is integral to clinical diagnosis with cystic fibrosis. Sweat chloride analysis is widely performed in a standardized fashion, with welldefined differences in values from those observed in the population without cystic fibrosis [26] [27] [28] [29] . A variant was deemed disease causing by clinical criteria if the mean sweat chloride concentration derived from at least three individuals carrying the variant was ≥60 mM 28, 30 . The use of an average measure enabled accommodation of individuallevel variability in sweat chloride concentration due to non-CFTR factors (Supplementary Fig. 1 ). When data were only available from two individuals, both sweat chloride concentrations had to exceed 90 mM. To attribute sweat chloride concentration to the variant under study, we analyzed individuals who carried a variant in their other CFTR gene that was known to cause complete or near-complete loss of CFTR function (Online Methods). Of the 159 variants under study, 140 met clinical criteria for causing cystic fibrosis ( Fig. 2) , of which 138 had sweat chloride concentrations derived from 3 or more individuals, whereas 2 variants each had measures exceeding 90 mM in 2 individuals (Supplementary Table 2 
Functional analysis
Two common variants (>5% frequency in the general population) in a polythymidine region in intron 9 (c.1210-12T(5) and c.1210-12T (7); legacy names 5T and 7T, respectively) that have been extensively studied were not reanalyzed here (Supplementary Note). Eighty of the remaining 157 variants are predicted to introduce a premature CFTR2 database 39 Figure 1 Data collected for the CFTR2 project. The 159 variants seen in 9 or more alleles with an allele frequency of ≥0.01% in CFTR2 were prioritized for further analysis. a Sweat chloride data were not reported for 10,170 affected individuals; 236 individuals had sweat chloride values outside the physiologic range (>150 mM or <5 mM) and were excluded. b Lung function data recorded as forced expiratory volume in 1 s (FEV 1 ) were not reported for 10,197 individuals; 5,633 individuals were under the age of 6 years and were excluded, if measurements were present, and 46 individuals had lung function measurements outside the physiological range (<3% or >150% predicted) and were excluded. c Pancreatic status was characterized as sufficient (PS) or insufficient (PI); data were not reported for 5,083 individuals. d Incomplete clinical information available from the submitting registry at the time of analysis. npg 1 1 6 2 VOLUME 45 | NUMBER 10 | OCTOBER 2013 Nature GeNetics A r t i c l e s termination codon (PTC) into CFTR mRNA (nonsense variants (n = 35), variants in the canonical nucleotides of the splice donor or splice acceptor sites (GT-AG; n = 15) or insertion-deletion variants causing frameshifts (n = 30); Fig. 3) . A common consequence of a PTC variant is nonsense-mediated decay (NMD) of mRNA, resulting in a severe reduction in mRNA levels and no protein produced 31, 32 . In rare cases, variants affecting splicing can create stable in-frame transcripts through the skipping of in-frame exons; however, the translated protein is almost invariably non-functional (for example, c.1393-1G>A (legacy name 1525-1G>A)) 33 . Thus, these 80 CFTR variants were predicted to be clinically deleterious 4 and cystic fibrosis causing ( Supplementary Fig. 2 ). Ten variants occurred within or near splice sites but did not alter canonical splice donor or acceptor sites ( Fig. 3) . Five of these variants have previously been evaluated and shown to express aberrant alternatively spliced transcripts in relevant tissues, leading to severe reduction in the levels of full-length CFTR mRNA (0-8% of the level for wild-type CFTR) [34] [35] [36] [37] [38] [39] ( Supplementary  Table 3a ). The remaining five putative splice variants were studied using minigene analysis (Online Methods and Supplementary  Table 3b ). Aberrant splicing (resulting in <10% wild-type CFTR transcript) and reduced levels of mature CFTR protein (<10% of the levels of wild-type CFTR) were observed for four of the five variants ( Supplementary Table 3c ). Less than 10% of wild-type CFTR function has generally been accepted as a conservative threshold for the presence of cystic fibrosis features in the exocrine pancreas, sweat gland and lungs 38, 40, 41 . Together, nine of the ten variants that affected splicing had evidence of deleterious consequences consistent with disease ( Fig. 3) .
Sixty-seven variants are predicted to result in either an amino acid substitution (missense; n = 65) or the omission of a single amino acid (in-frame deletion; n = 2). As these variants permit the synthesis of stable mRNA and full-length protein, we performed experimental studies on each variant in isolation to determine its effect on CFTR biogenesis and function. We expressed CFTR bearing missense or in-frame changes in HeLa and Fischer rat thyroid (FRT) cells to assess glycosylation status with protein blotting, a well-established method to monitor CFTR maturation (Supplementary Note) 42, 43 . We tested 63 (61 missense and 2 in-frame deletion) of the 67 variants in both cell lines for their effect on CFTR processing. Results from the two cell lines largely agreed (r 2 = 0.94; P < 0.001; Supplementary Fig. 3 ). The variants fell into three groups: those with minimal disruption in processing (>80% CFTR protein in the mature form in both cell lines; n = 32), those with intermediate disruption in processing (10-80% CFTR protein in the mature form in at least one cell line; n = 21) and those with a dramatic negative effect on processing (≤10% CFTR protein in the mature form in both cell lines; n = 10). In the group with intermediate effects on processing, 11 variants caused a severe defect in processing in 1 cell line but not in the other; the remaining 10 variants caused a defect of intermediate severity in both cell lines.
To assess the effect of the missense variants on CFTR function, we measured chloride currents in FRT cells expressing CFTR bearing each of 63 variants individually (61 missense and 2 in-frame deletion). Chloride conductance was not determined for four missense variants. Functional analysis of primary airway cells obtained Figure 2 The process used to define CFTR variants as cystic fibrosis causing on the basis of a biochemical measure. The mean sweat chloride concentration was evaluated for individuals with a given variant in trans with a known cystic fibrosis (CF)-causing variant (16 commonly occurring pancreatic-insufficient variants among the 23 originally identified as cystic fibrosis causing in the ACMG panel) 65 Figure 3 The process used to define CFTR variants as cystic fibrosis causing on the basis of functional analysis. Variants were sorted by their predicted effect. Those expected to disrupt the amount or quality of mRNA included variants that introduce a PTC and therefore result in no protein (variants with introduction of a stop codon, variants that affect splice donor or acceptor sites, insertion or deletion changes variants introduce a frameshift) and variants predicted to result in altered mRNA splicing efficiency and therefore reduced production of full-length CFTR protein. Variants predicted to produce full-length CFTR protein but with an amino acid substitution, insertion or deletion (missense and insertion or deletion changes that do not introduce a frameshift) were evaluated to determine protein level (defined as the percentage of mature protein present) or function (defined as the percentage of chloride current) relative to wild-type (WT) CFTR. Variants were considered disease causing if they resulted in less than 10% of the level of wild-type CFTR mRNA transcript, wild-type CFTR protein or wild-type CFTR chloride current. a Two common variants in intron 9 that have a complex effect on the cystic fibrosis phenotype and have been extensively studied were excluded from further analysis. b Variants known to cause additional consequences include c.1393-1G>A (legacy name 1525-1G->A), which skips an inframe exon; p.Glu831*, which results in an alternatively spliced mRNA in addition to the synthesis of a truncated protein; and p.Glu1418Argfs*14, in which the deletion in the final exon would not be expected to cause NMD. Each of these variants is associated with a mean sweat chloride concentration above 60 mM (supplementary Fig. 2 from individuals with cystic fibrosis bearing nine different CFTR genotypes composed of established disease-causing variants was consistent with a threshold of 10% CFTR function being associated with cystic fibrosis (Supplementary Fig. 4 ). Forty-three variants (41 missense and 2 in-frame deletion) conducted chloride at a level less than 10% of that observed with wild-type CFTR and were deemed disease causing ( Fig. 3) . CFTR bearing each of the remaining 20 missense changes generated chloride conductance that ranged from 10.5% to 147% of that of wild-type CFTR. As such, the effects of these 20 variants on CFTR function were classified as inconsistent with cystic fibrosis, although these variants could contribute to other disease phenotypes. Comparison of CFTR processing and chloride current showed that a severe processing defect in HeLa or FRT cells (C band/(B band + C band) < 0.1) was consistently associated with CFTR chloride channel function of less than 10% of wild-type function ( Supplementary Fig. 5 and Supplementary Note). Of the four variants for which we did not measure chloride conduction, one (p.His199Tyr) exhibited a severe processing defect in HeLa cells (<0.01) and was categorized as functionally deficient (Fig. 3) . The remaining three variants (p.[Gln359Lys; Thr360Lys], p.Leu558Ser and p.Arg1070Gln) exhibited processing greater than 10% of that of wild-type CFTR and were not functionally classified.
Penetrance analysis
Of the 159 variants studied, 127 met clinical and functional criteria and were classified as cystic fibrosis-causing variants ( Fig. 4 and Supplementary Table 2 ). To aid in the classification of variants not meeting clinical or functional criteria, we performed a penetrance study using 2,188 fathers of individuals with cystic fibrosis recruited from North America and Europe (Supplementary Table 4 ). The presence of a normally functioning CFTR gene is required in fathers of individuals with cystic fibrosis, as reduced CFTR function is associated with male infertility due to congenital bilateral absence of the vas deferens (CBAVD) 44 . Male infertility due to CBAVD affects 97-98% of males with cystic fibrosis 45, 46 . Fathers of naturally conceived offspring with cystic fibrosis will transmit one pathogenic allele to their affected children. As those fathers are fertile, the non-transmitted allele should not contain a deleterious variant. Thus, any CFTR variants occurring on the non-transmitted allele in a fertile father was deemed nonpenetrant for cystic fibrosis and CBAVD. To exclude errors that could have occurred during sample processing or if assisted reproductive technologies were used without our knowledge, we required that a variant be observed on the non-transmitted CFTR allele in at least two fathers.
Genotyping for the 159 CFTR variants yielded 2,062 samples suitable for penetrance analysis, of which 185 had 2 or more variants ( Supplementary Figs. 6 and 7) . After additional filtering, we found that 100 fathers carried at least 1 of the 159 variants in trans with a previously accepted cystic fibrosis-causing variant ( Supplementary  Fig. 6 ). Using data from these 100 fathers, we deemed 10 variants non-penetrant, as each occurred in the non-transmitted 'healthy' CFTR gene of at least 2 fathers ( Table 1) . To assess the validity of labeling these variants as non-penetrant, we compared the frequency of each variant in the fathers and in the CFTR2 database with its frequency in data available from the 1000 Genomes Project 47 . Our first premise was that non-penetrant and phenotypically irrelevant variants should occur in healthy cystic fibrosis-carrier fathers on the non-transmitted allele at the same frequency as observed in the general population. This was the case for nine non-penetrant variants for which 1000 Genomes Project data were available ( Table 1) . The second premise was that non-penetrant variants should occur at a much lower frequency in individuals with cystic fibrosis than in the general population. Indeed, the frequency of each nonpenetrant variant in individuals with cystic fibrosis enrolled in CFTR2 was at least tenfold lower than the frequency in the general population where 1000 Genomes Project data were available. In addition to these ten variants, c.1210-12(7) (legacy name 7T) had already been reported to be non-penetrant 48 49 .
We found no evidence of non-penetrance in the screen of fathers for 147 variants (all 127 that met clinical and functional criteria as well as 8 variants that met only clinical criteria, 6 variants that met only functional criteria and 6 variants that met neither criteria; Fig. 4) . Included among the variants meeting neither clinical nor functional criteria are those that have previously been associated with variable penetrance (such as p.Asp1152His), variants that have been reported as part of complex alleles in which the disease liability of each variant individually could not be determined (such as the pair p.Arg74Trp and p.Asp1270Asn) and variants with incomplete clinical or functional analysis.
DISCUSSION
Genetic testing of CFTR is widely employed for diagnosis in symptomatic individuals 29 , for carrier status in the general population 17 , increasingly as part of newborn screening 50, 51 and most recently for selection for treatment with variant-specific molecular therapy 52 . The primary goal of the CFTR2 project was to increase the fraction of variants in the CFTR gene that have been assessed for their propensity to cause disease. At the initiation of the project, 23 variants were defined as disease causing 11 . Combining phenotypic evidence with functional analysis enabled unambiguous assignment of pathogenicity to an additional 104 variants. Testing for all 127 variants is estimated to account for 95.4% of cystic fibrosis-conferring alleles in our sample, leaving only 0.21% of affected individuals in our sample without at least one pathologic CFTR variant identified. Couples undergoing carrier screening will also benefit, as the sensitivity for detecting couples at a 1 in 4 risk of having a child with cystic fibrosis should increase from 72% to ~91% when screening for the 127 pathogenic variants. It should be noted that these estimated detection rates are subject to geographic and ancestry-based variability in variant distribution and frequency. This project illustrates the feasibility of translating allelic diversity into clinical application but also highlights the challenges in interpreting the disease implications of rare DNA changes.
The CFTR2 project gathered both genotype and phenotype data on individuals who were enrolled in registries and clinics. This approach enriched the pool of affected individuals, but we also used additional objective measures to differentiate variants causing life-shortening cystic fibrosis from those causing less severe disease 44 . Notably, 19 of 159 variants studied (12%) did not meet our clinical threshold, despite being reported in individuals diagnosed with cystic fibrosis by a medical professional familiar with the disease. This finding shows the degree of phenotypic heterogeneity existing even within well-annotated clinical data collections. Of the 140 variants identified as disease causing using clinical criteria, 13 (9.3%) did not meet functional criteria. Our study emphasizes the importance of using both phenotypic and functional analysis to clinically annotate variants found in affected individuals and demonstrates that the presence of a rare variant, even if reported in multiple unrelated affected individuals, does not ensure that it is deleterious or pathogenic.
Phenotypic and functional criteria for disease can be based on metrics that already exist for many genetic diseases. For this study, we chose sweat chloride concentration to define the phenotype because it is dependent on CFTR function, correlates with disease severity, is measured frequently in a standardized fashion and has well-validated cutoffs between normal and disease levels 29, 30 . Similarly, assessment of the functional effects of variants can follow established guidelines 4 . For example, the assumption that variants predicted to introduce a PTC are deleterious is commonly accepted practice 4 . As noted here, the clinical features of individuals carrying predicted PTC variants are consistent with disease ( Supplementary Fig. 2) . Evaluation of the effect of missense variants poses the greatest hurdle; however, relatively straightforward assays such as protein blotting can disclose processing defects, a common consequence of amino acid substitutions. Expression of mutated protein in multiple cell lines, as employed here, minimizes cell type-specific effects. Perhaps the most challenging issue is the establishment of thresholds for both phenotypic and functional measures. In this study, the adopted thresholds were vetted by experts in the clinical and functional areas of cystic fibrosis research. The 10% threshold for protein expression and chloride conductance (both in comparison to wild-type CFTR) is not an absolute demarcation between disease and health but is a conservative threshold consistent with previous research correlating CFTR function with disease 38, 40, 41 . Provided that it is acknowledged that consensus opinions represent the current understanding of pathogenesis, thresholds can be modified if warranted by future studies, as some variants may influence CFTR in a manner not captured by our methods.
The 127 variants that met both clinical and functional criteria were designated cystic fibrosis causing; however, 32 remaining variants (20%) required further analysis to determine whether they were neutral with respect to disease or associated with a milder phenotype or partial penetrance. Demonstration that a variant occurs in a sample of normal controls at the same frequency as observed in affected individuals has been a long-accepted method to determine neutrality 53, 54 . Under recessive inheritance conditions, this test can only be performed in 'control' individuals known to carry a deleterious allele in trans. Fathers of individuals with cystic fibrosis provide an ideal group to assess neutrality, as they carry a functional CFTR gene by virtue of their fertility and a disease-causing variant transmitted to their affected offspring. Demonstration that a variant under study occurs in the healthy (non-transmitted) CFTR genes of fertile fathers provides compelling evidence of neutrality or non-penetrance for cystic fibrosis. The power of this approach depends on the frequency of the alleles in the population and the number of 'controls' tested. In tests of the non-transmitted (non-cystic fibrosis) chromosome of fertile fathers, confidence that a given variant was not found because it is fully penetrant declines as the allele frequency declines. Therefore, we are more confident that more frequent variants such as p.Gly551Asp are fully penetrant than we are for variants such as p.[Gln359Lys; Thr360Lys], p.Phe1052Val and p.Gly1069Arg, which were seen with an allele frequency of less than 0.0002. Additional confidence in the assignment of variants is derived from the observation that variants that were non-penetrant for cystic fibrosis occurred at similar frequencies in individuals with cystic fibrosis and subjects of European ancestry in the 1000 Genomes Project. Penetrance analysis should become more useful for clinical applications as the frequencies of rare variants in the healthy population become more robust and complete (for example, with 100,000 genomes) and with more complete delineation of ancestry-based and geographic cohorts, to which we did not have access.
The instances in which the apparent disease liabilities determined by clinical, functional and penetrance criteria were discordant deserve special attention. For the 13 variants meeting clinical but not functional criteria, a common finding was the presence of additional variants in cis that ablated or modified CFTR function, thereby explaining the presence of these variants in individuals with cystic fibrosis. Recognizing that complex alleles may account for discordance between phenotype and genotype is critical in the clinical arena, as misidentification can lead to inappropriate medical actions. These findings emphasize that complete sequencing of the coding regions of genes bearing rare or novel alleles should be undertaken to identify all potentially deleterious alleles. Finally, penetrance analysis was helpful in distinguishing variants that might contribute to disease from those that were neutral. Included in the group not causing cystic fibrosis are known polymorphic variants such as p.Met470Val 55,56 that seem to have been entered into patient registries owing to incomplete genotyping of CFTR. Individuals carrying variants not causing cystic fibrosis such as p.Met470Val with symptoms indicative of cystic fibrosis may benefit from being regenotyped. Conversely, individuals diagnosed with cystic fibrosis on the basis of genetic findings of one or more variants now considered not to cause cystic fibrosis should be re-evaluated.
Although this work establishes disease liability for most of the alleles found in individuals with cystic fibrosis, 20 variants remain indeterminate. The ACMG has issued recommendations for the classification of unknown variants beyond those used in this study 4, 57 ; however, probabilistic estimation may not be appropriate for all variants deemed indeterminate after extensive clinical, functional and penetrance analyses. As a purpose of this project is to definitively place CFTR variants into well-defined categories, further classification of indeterminate variants will require additional analysis to quantify the probability of causing or not causing disease. For example, it is possible that one or more of the indeterminate variants cause dysfunction of CFTR in a manner distinct from the functional assessments used in this study, as has been shown for two missense changes that also affect RNA splicing (p.Gly576Ala 58 and p.Ile1234Val; A.S.R. and M.D.A., unpublished data).
The indeterminate variants as well as over 1,600 CFTR variants that are unclassified remain a diagnostic dilemma. Computational approaches predicting disease liability have been applied to splicesite 59 and missense [19] [20] [21] changes to classify CFTR variants. These approaches lack the specificity needed for definitive clinical classification. Algorithms that predict splicing are useful for highly conserved sequences, but experimental studies are needed to analyze the effects of changes to nucleotides that are less well conserved or are located outside of consensus splice sites, as shown in the Supplementary Note 59, 60 . Given the large and diverse structure of the full-length CFTR protein (1,480 residues in length), annotation of more variants for algorithmic training should substantially improve the predictive performance of the classifier. To that end, machine learning approaches could prioritize future experimental testing.
Increased use of sequencing in the clinical setting has emphasized the medical challenges posed by rare variants. Although it appears to be a daunting task to determine the disease liability of all variants accounting for a mendelian disease, the CFTR2 project demonstrates the feasibility of the task using a phenotype-driven approach. Patient registries have been assembled for many genetic disorders 61-63 that should enable the collation of patient genotype and associated phenotype data for detailed analysis. Microattribution can identify the data source and composition, while acknowledging the contributor and data integrity 64 . For recessive disorders, the number of alleles of each gene in the human population is finite and stable (excepting extremely rare de novo variants). Thus, careful assignment of disease liability to the variants responsible for these disorders will be valuable for current and future generations of patients and their family members. 
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Subjects. Anonymized genotype and cross-sectional clinical information were collected from 25 national cystic fibrosis registries and major clinical centers in countries without a registry (listed in the Acknowledgments and in Supplementary Table 1 ). Genotype was recorded from the clinical record. For 13 data sets (7.5% of subjects), clinical information was provided only for individuals carrying at least one variant not included in the ACMG panel for cystic fibrosis screening 11 . Sweat chloride concentration, measured at the time of diagnosis and averaged if performed more than once, was recorded in mM (mEq/l). Results from 236 affected individuals (1% of measurements) were excluded because they were not within the physiological range of 5-150 mM 29 . Pancreatic status, defined differently by registry, was recorded from the submitting registry. Raw FEV 1 in liters was converted to percent predicted using subject age, sex, ancestry (if known) and height in the Wang equation (for individuals under 18 years old) or the Hankinson equation (for individuals 18 years and older) 67, 68 . Otherwise, FEV 1 percent predicted was used as provided; the most recent measurement within the last recorded year was used. Clinical features ascribed to a CFTR variant were derived from subjects bearing the variant in trans with a cystic fibrosis-causing variant previously shown to have minimal residual function 65 and were averaged across subjects with that particular genotype (variant of interest/known cystic fibrosis-causing variant genotype). All data collection was approved by the Institutional Review Board at Johns Hopkins University and by the Registry Advisory Committee for the US Cystic Fibrosis Foundation.
Analysis of variants expected to affect RNA splicing. CFTR variants predicted
to alter splicing efficiency that were not previously studied ( Supplementary  Table 2 ) were examined to confirm their deleterious nature using minigene constructs as previously described with some modifications 69 . Briefly, a fivestep strategy was employed. First, we amplified the 5′-acceptor and 3′-donor splice-site sequences of the intronic region of interest along with flanking exons from genomic DNA using KOD Hot-Start DNA polymerase (Novagen). Primer sequences are available upon request. Second, fusion PCR was performed on the amplicons generated in the first step using only the exonic primers, creating a fusion amplicon with 5′-acceptor and 3′-donor splice-site sequences with respective exons on either side. Third, we performed sticky feet mutagenesis of pcDNA5/FRT/CFTR using the fusion PCR amplicon as the primer to create a pcDNA5/FRT/CFTR minigene 70 . Fourth, we used site-directed mutagenesis (QuikChange II XL, Agilent Technologies) to create the c.579+3A>G (legacy name 711+3A>G), c.579+5G>A (legacy name 711+5G>A), c.1585-8G>A (legacy name 1717-8G>A), c.2657+2_2657+3insA (legacy name 2789+2insA) and c.2988G>A (legacy name 3120G>A) variants ( Supplementary Table 3c ) in the respective minigenes. The additional splice-site variants c.579+1G>T (legacy name 711+1G>T) and c.2988+1G>A (legacy name 3120+1G>A) were created as positive controls in the assay. Primer sequences are available upon request. Finally, we recloned the full-length wild-type and mutant CFTR minigene constructs into pcDNA5/FRT vector to eliminate the possibility that nucleotide errors were introduced during the mutagenesis steps 71 . Sequence confirmation of the wild-type and mutant minigenes was performed on an ABI 3100 Genetic Analyzer (Applied Biosystems). Wild-type and mutant minigene plasmids were transfected into human embryonic kidney (HEK) 293 cells (ATCC) and cystic fibrosis bronchial epithelial (CFBE 41o-) cells (a generous gift from D. Gruenert). All cell lines used were tested for mycoplasma contamination at the Cell Core Center and Biorepository at Johns Hopkins University (Baltimore, Maryland, USA). Forty-eight hours after transfection, total RNA and whole-cell lysates were prepared. First-strand cDNA was synthesized using the iScript cDNA synthesis kit (Bio-Rad) or SuperScript RT III reverse transcriptase and random hexamers (Invitrogen). The resulting cDNA product was used directly for PCR amplification with exonic primers from the regions of interest. Primer sequences are available upon request. Agarose gel (1.5%) electrophoresis was performed to analyze the RT-PCR products, and transcripts were sequenced after gel extraction. RNA quality for all samples was verified by amplification of the transcript encoding the TATA box-binding protein (TBP). Controls without reverse transcriptase and without RNA were included. The amount of correctly spliced product from each CFTR-mutant minigene relative to the amount of the respective wild-type minigene was calculated from the sequencing data as described previously 72 .
Protein blot analysis was performed to evaluate the amount of complex glycosylated (C-band) CFTR. Mouse monoclonal antibodies 570 (R domain or 596; NBD2, UNC antibody distribution program sponsored by Cystic Fibrosis Foundation Therapeutics) and/or MM13-4 (N terminal; Chemicon) were used (1:5,000 dilution) to detect CFTR. GAPDH or tubulin was used as a loading control. Blots were quantified using ImageJ software (NIH) to determine the amount of processed CFTR (C band) for each experimental sample relative to the amount produced by the wild-type minigene.
Analysis of variants expected to alter protein processing and/or function.
Variants causing an amino acid substitution or an in-frame deletion were introduced individually into CFTR cDNA using site-directed mutagenesis as previously described 73 . The wild-type CFTR clone was obtained from an individual who did not have cystic fibrosis and encoded the known neutral variant p.Val1475Met. Transient expression of CFTR in HeLa cells (Clontech) was achieved as described previously 43 . Stable expression of CFTR in FRT cells (a kind gift from M. Welsh) was achieved by integrating each mutated CFTR cDNA as a single copy into the same genomic location using the Invitrogen Flp-In system as described previously 73, 74 . After selection and confirmation of expression of the CFTR cDNA with the desired variant, the levels of heterologous human CFTR mRNA were determined for each cell line. Cell lines with mRNA levels of >0.5-fold or <3-fold the average level of four independent FRT cell lines expressing wild-type CFTR were tested. CFTR maturation and the amount of protein expression were quantified using the ratio of C-band CFTR to B-band + C-band CFTR (normalized to wild-type CFTR as described previously) 43 . Forskolin-activated, CFTR-dependent chloride secretion was measured in confluent FRT cells by short-circuit current (I sc ) in Ussing chambers. I sc measurements were repeated 3 to 14 times per cell line and averaged. All readings were reported as a percentage of the average I sc of wild-type CFTR-expressing FRT cell lines 75 . Measurements from four separate FRT cell lines were used to establish the mean current and variance of wild-type CFTR. Human bronchial epithelial (HBE) cells were isolated from subjects with and without cystic fibrosis, and I SC was measured as previously described 76 .
MassARRAY assays. An assay to screen for the 159 CFTR variants seen in ≥0.01% of affected individuals was developed using open-platform matrixassisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectroscopy 77 . The assay was validated using genomic DNA controls obtained from available study stocks from the United States (n = 99), France (n = 18), Canada (n = 22), the Czech Republic (n = 2) and Serbia (n = 1). When genomic DNA was not available (n = 11), plasmid DNA was generated using the QuikChange II Site-Directed Mutagenesis kit (Agilent Technologies). We were unable to confirm two variants because of a problem with the extension primer (p.Gly330*) and an inability to derive a positive control (p.Glu1418Argfs*14). The assay was validated with Sanger sequencing. In validation studies, 35 of 35 variants were identified, and 29 of 29 wild-type chromosomes were confirmed.
The multiplex assay design was initially accomplished using Assay Designer Software, Version 4.0 (Sequenom) to design both amplification and extension primers and was subsequently optimized using results with the positive controls. Multiplex PCR amplification of regions of up to 300 nt in length from genomic DNA, whole genome-amplified DNA or plasmid DNA at a concentration of 25, 50 or 5 ng/µl, respectively, was performed in 384-well plates. The reaction contained reagents from the iPLEX Gold SNP Genotyping kit (Sequenom). Because of variation in amplicon lengths and the likelihood of primer-dimer formation, differential primer concentrations were used. Primer multiplexes were evaluated for possible dimers and hairpins using NIST primer tools (see URLs) and subsequently adjusted. Details of primer sequences and the concentrations used are available upon request. Unincorporated dNTPs were neutralized using reagents from the iPLEX Gold Reagent kit (Sequenom).
Single-base extension products were generated from each purified PCR reaction using reagents from the iPLEX Gold Reagent kit. The resulting single-base extension PCR products were prepared for mass spectrometry and dispensed to a SpectroCHIP (Sequenom). Data were analyzed using a MALDI-TOF spectrometer (Sequenom). Data were generated with SpectroACQUIRE software version 3.0 on the MassARRAY spectrometer (Sequenom) and then analyzed using Typer software, version 4.0.22 (Sequenom). This assay was npg employed to test DNA from the fathers of offspring with cystic fibrosis for variants suspected of being cystic fibrosis causing. Fathers provided informed consent for genetic study and were anonymized for analysis. Each father should carry only the deleterious CFTR variants passed to his offspring. Additional variants detected in fathers represent either a complex allele in which two CFTR variants are present on the same chromosome or a CFTR variant in trans with the transmitted variant that is insufficiently deleterious to make the father infertile. Fathers with a cystic fibrosis-causing variant and a second variant had their offspring genotyped if available (n = 145) to delineate phase.
Statistical analysis. Statistical analyses were performed using Intercooled Stata version 11 (StataCorp) using the METAREG plug-in (see URLs). A meta-analysis approach was used to compare clinical features in subjects with PTC versus non-PTC variants and to perform regression analysis of aggregate data for each cell line. We incorporated the observed variance across subjects for each variant and allowed for heterogeneity of variance across variants to compare groups. Group means (for chloride current) were compared under a random-effects model accounting for statistical variance in the measurements both within and across the variant groups. All reported regression coefficients are unstandardized.
